Please login to the form below

Not currently logged in

CanSinoBIO considers booster jab for COVID-19 vaccine

Chinese biotech company said the efficacy rate for the one-dose vaccine could decrease over time

The efficacy of Chinese biotech company CanSino Biologics's (CanSinoBio) single-dose COVID-19 vaccine could decrease over time, according to the company’s chief scientific officer Zhu Tao.

During an online presentation on Wednesday, Tao said that the vaccine is likely to retain an efficacy rate of 50% or more five to six months after initial vaccination.

According to the World Health Organization (WHO), a vaccine must have at least a 50% efficacy rate to be considered effective in preventing COVID-19.

Tao added that a booster dose is being considered, with trial participants potentially set to receive a second jab around six months after their first dose.

“A booster shot six months later led to a seven times to ten-times increase in neutralising antibody levels, so we expect in this case efficacy could reach over 90%,” said Tao.

He said, however, that further clinical trial data is required before the exact efficacy can be determined.

Earlier this year, CanSinoBIO revealed that its vaccine was 65.7% effective at preventing symptomatic COVID-19 cases, based on an analysis from late-stage trials, although this dropped to 65.28% after two weeks.

The one-dose COVID-19 vaccine has been approved for use in China, Pakistan, Hungary and Mexico.

Another single-dose vaccine, developed by Johnson & Johnson (J&J), recently received EU authorisation after proving effective in late-stage trials.

J&J’s vaccine was found to be 66% effective overall in preventing moderate-to-severe COVID-19, 28 days after vaccination.

The data also demonstrated that the vaccine was 85% effective in preventing severe disease across all regions and showed protection against COVID-19-related hospitalisation and death, beginning 28 days after vaccination.

Single-dose vaccines have been identified as particularly useful during the pandemic, with advantages including easier storage and ease of use as people are not required to return for a second injection.

mRNA-based vaccines, such as Pfizer/BioNTech and Moderna’s respective jabs, have higher efficacy rates compared to both CanSinoBIO and J&J’s vaccines, but also require ultra-low storage temperatures and are administered as part of a two-dose regimen.

This has raised storage and distribution issues – particularly in developing countries which may not have the infrastructure to support the wide-spread rollout of this type of vaccine.

Article by
Lucy Parsons

1st April 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....